Pyxis Oncology, Inc. (NASDAQ: PYXS) is a Healthcare company (Biotechnology) with a market capitalization of $172M. The Maz Rating grades it against the other companies in its sector.
Pyxis Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.44, Pyxis Oncology, Inc. trades at 15.2x sales and 2.8x book value. Over the last twelve months it generated about $11M of revenue and a net loss of $159M. It runs a gross margin of 99.8%, an operating margin of -807.8% and a net margin of -785.5%. It shows return on equity of -252.4%, return on invested capital of -151.9% and a free cash flow yield of -41.2%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 2.96. Over the past 52 weeks the share price ranged from $1.03 to $5.55, with a beta of 1.41.
Pyxis Oncology, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Pyxis Oncology, Inc. (PYXS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.14% / 30% · (Cash+Inv) / Mkt Cap (36m) 33.6% / 30% · Interest income / Revenue 53900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.14% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 33.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 53900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.14% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 33.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 53900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 1.90% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 68.8% / 33.33% · Receivables / Avg Assets (4Q) 0.24% / 33.33% · Interest income / Revenue 53900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 2.46% / 33.33% · (Cash+ST Inv) / Total Assets 72.4% / 33.33% · (Cash+Recv) / Total Assets 72.4% / 33.33% · Interest income / Revenue 53900000.0% / 5% | Fail |
No. As of September 2026, Pyxis Oncology, Inc. (PYXS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Pyxis Oncology, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 53900000.0% of each dividend: Pyxis Oncology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.